Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company, has announced its participation in the Renmark Financial Communications Virtual Non-deal Roadshow Series. The event will feature a presentation and live Q&A session on Wednesday, October 23, 2024, at 12 PM EDT.
Mr. Robert Bitterman, CEO and Chairman of the Board, will lead the presentation. Phio Pharmaceuticals specializes in INTASYL® siRNA gene silencing technology, designed to enhance immune cells' effectiveness in killing tumor cells.
Stakeholders, investors, and interested individuals are invited to register and attend this live event. A replay will be available on the Renmark Financial Communications Inc. website. To ensure smooth connectivity, attendees are advised to use the latest version of Google Chrome when accessing the registration link.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), una società biotecnologica in fase clinica, ha annunciato la sua partecipazione alla serie di Roadshow Virtuali senza offerta di Renmark Financial Communications. L'evento presenterà una presentazione e una sessione di domande e risposte dal vivo mercoledì 23 ottobre 2024, alle 12 PM EDT.
Il signor Robert Bitterman, CEO e Presidente del Consiglio, guiderà la presentazione. Phio Pharmaceuticals si specializza nella tecnologia di silenziamento genico con INTASYL® siRNA, progettata per migliorare l'efficacia delle cellule immunitarie nell'uccidere le cellule tumorali.
Stakeholder, investitori e persone interessate sono invitati a registrarsi e partecipare a questo evento dal vivo. Una registrazione sarà disponibile sul sito web di Renmark Financial Communications Inc. Per garantire una connessione fluida, si consiglia ai partecipanti di utilizzare l'ultima versione di Google Chrome quando accedono al link per la registrazione.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), una empresa de biotecnología en etapa clínica, ha anunciado su participación en la serie de Roadshows Virtuales sin oferta de Renmark Financial Communications. El evento contará con una presentación y una sesión de preguntas y respuestas en vivo miércoles 23 de octubre de 2024, a las 12 PM EDT.
El Sr. Robert Bitterman, CEO y Presidente de la Junta, liderará la presentación. Phio Pharmaceuticals se especializa en la tecnología de silenciamiento genético de INTASYL® siRNA, diseñada para aumentar la efectividad de las células inmunitarias en la eliminación de células tumorales.
Los interesados, inversionistas y partes interesadas están invitados a registrarse y asistir a este evento en vivo. Una repetición estará disponible en el sitio web de Renmark Financial Communications Inc. Para asegurar una conectividad fluida, se aconseja a los asistentes que usen la última versión de Google Chrome al acceder al enlace de registro.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO)는 임상 단계의 생명공학 회사로, Renmark Financial Communications의 비거래 가상 로드쇼 시리즈에 참여한다고 발표했습니다. 이 행사는 2024년 10월 23일 수요일 오후 12시 EDT에 프레젠테이션과 라이브 Q&A 세션으로 진행됩니다.
로버트 비터먼(CEO 겸 이사회 의장)이 프레젠테이션을 이끌 예정입니다. Phio Pharmaceuticals는 종양 세포를 죽이는 면역 세포의 효능을 향상시키기 위해 설계된 INTASYL® siRNA 유전자 침묵 기술을 전문으로 합니다.
이벤트에 참여하고자 하는 이해관계자, 투자자 및 관심 있는 개인들은 등록하고 참석할 수 있습니다. Renmark Financial Communications Inc. 웹사이트에서 재방송이 제공될 예정입니다. 원활한 연결을 위해 참석자들은 등록 링크에 접속할 때 최신 버전의 Google Chrome을 사용하는 것이 좋습니다.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), une entreprise de biotechnologie en phase clinique, a annoncé sa participation à la série de Roadshows Virtuels sans proposition de Renmark Financial Communications. L'événement inclura une présentation et une session de questions-réponses en direct le mercredi 23 octobre 2024, à 12h EDT.
M. Robert Bitterman, PDG et Président du Conseil, dirigera la présentation. Phio Pharmaceuticals se spécialise dans la technologie de silençage génique INTASYL® siRNA, conçue pour améliorer l'efficacité des cellules immunitaires dans l'élimination des cellules tumorales.
Les parties prenantes, investisseurs et personnes intéressées sont invités à s'inscrire et à assister à cet événement en direct. Un replay sera disponible sur le site de Renmark Financial Communications Inc. Pour garantir une connexion fluide, il est conseillé aux participants d'utiliser la dernière version de Google Chrome lors de l'accès au lien d'inscription.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), ein Biotechnologieunternehmen in der klinischen Phase, hat seine Teilnahme an der Renmark Financial Communications Virtual Non-Deal Roadshow Series bekanntgegeben. Die Veranstaltung wird eine Präsentation und eine Live-Q&A-Session am Mittwoch, den 23. Oktober 2024, um 12 Uhr EDT umfassen.
Herr Robert Bitterman, CEO und Vorsitzender des Vorstands, wird die Präsentation leiten. Phio Pharmaceuticals spezialisiert sich auf INTASYL® siRNA-Gentechnologie, die entwickelt wurde, um die Effektivität von Immunzellen beim Abtöten von Tumorzellen zu erhöhen.
Stakeholder, Investoren und interessierte Personen sind eingeladen, sich zu registrieren und an dieser Live-Veranstaltung teilzunehmen. Eine Wiederholung wird auf der Website von Renmark Financial Communications Inc. verfügbar sein. Um eine reibungslose Verbindung zu gewährleisten, wird den Teilnehmern empfohlen, beim Zugriff auf den Registrierungslink die neueste Version von Google Chrome zu verwenden.
- None.
- None.
Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDT
Marlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, announced today that management will present in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc.
Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present on Wednesday, October 23, 2024, at 12 PM EDT. A replay of the event may be accessed on the Renmark Financial Communications Inc. website at https://www.renmarkfinancial.com/vndrs.
Phio Pharmaceuticals welcomes stakeholders, investors, and other individual followers to register and attend this live event.
REGISTER HERE:
To ensure smooth connectivity, please access the link above using the latest version of Google Chrome.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company focused on silencing specific genes using its proprietary INTASYL siRNA technology. In non-systemic applications, INTASYL can target and silence virtually any gene with high specificity across a wide range of tissue types. INTASYL is primarily designed to enhance the ability of immune cells to kill tumor cells and can play a key role in improving adoptive cell therapy. Notably, INTASYL is the only self-delivering RNAi technology, in that does not require specialized formulations or drug delivery systems.
For additional information, visit the Company's website, www.phiopharma.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs
Renmark Financial Communications Inc.
James R. Kautz: jkautz@renmarkfinancial.com
Tel: (416)-644-2020 or (212)-812-7680
www.renmarkfinancial.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/226600
FAQ
When is Phio Pharmaceuticals (PHIO) participating in the Renmark Financial Communications Virtual Non-deal Roadshow?
Who will be presenting for Phio Pharmaceuticals (PHIO) at the Virtual Non-deal Roadshow?
What is the main technology focus of Phio Pharmaceuticals (PHIO)?
How can investors attend the Phio Pharmaceuticals (PHIO) Virtual Non-deal Roadshow presentation?
Will there be a replay available for Phio Pharmaceuticals' (PHIO) Virtual Non-deal Roadshow presentation?
